Nexigen GmbH develops drugs for indications with unmet medical need. Our proprietary drugs utilize disease mechanisms, which are not accessible for common technologies. Therefore Nexigen aims to close with its drugs the significant gap between small molecule drugs and therapeutic antibodies. The company focuses currently on oncological indications. The proprietary technology platform is however widely applicable on various indications.
The strategy of Nexigen builds on selective partnerships in life science industry.
|Focus:||Drug discovery, therapeutic peptides, drug screening|